Locanabio Overview
- Year Founded
-
2016
- Status
-
Private
- Employees
-
64
- Latest Deal Type
-
Later Stage VC
- Investors
-
14
Locanabio General Information
Description
Developer of ribonucleic acid-targeting gene therapy platform designed for modifying disease-causing RNA for patients with rare genetic neuromuscular and neurodegenerative diseases. The company's platform uses gene therapy to target and correct disease-causing RNA and identifies multiple sequences of interest within the transcript and program targeting sequences, thereby helping medical practitioners to optimize and advance therapeutic candidates that are distinct from deoxyribonucleic acid-targeted approaches and nucleic acid-based ribonucleic acid targeting.
Contact Information
Website
www.locanabio.comCorporate Office
- 3545 John Hopkins Court
- Suite 200
- San Diego, CA 92121
- United States
Corporate Office
- 3545 John Hopkins Court
- Suite 200
- San Diego, CA 92121
- United States
Locanabio Timeline
Locanabio Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 8. Later Stage VC | 12-May-2023 | Completed | Pre-Clinical Trials | |||
| 7. Early Stage VC (Series B) | 14-Dec-2020 | Completed | Pre-Clinical Trials | |||
| 6. Grant | 12-Jun-2019 | Completed | Pre-Clinical Trials | |||
| 5. Early Stage VC (Series A) | 22-May-2019 | Completed | Pre-Clinical Trials | |||
| 4. Accelerator/Incubator | 16-Oct-2017 | Completed | Startup | |||
| 3. Seed Round | 06-Oct-2017 | Completed | Startup | |||
| 2. Grant | 07-Jun-2016 | $15K | Completed | Startup | ||
| 1. University Spin-Out | 01-Jan-2016 | Completed | Startup |
Locanabio Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate ($) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B | ||||||||
| Series A | ||||||||
| Seed | 4,198,152 | $0.000100 | $0.08 | $0.95 | $0.95 | 1x | $0.95 | 5.71% |
Locanabio Comparisons
Industry
Financing
Details
Locanabio Competitors (23)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| PepGen | Formerly VC-backed | Boston, MA | ||||
| NeuBase Therapeutics | Formerly VC-backed | Pittsburgh, PA | ||||
| WaVe Life Sciences | Formerly VC-backed | Cambridge, MA | ||||
| Voyager Therapeutics | Corporation | Cambridge, MA | ||||
| Fluxion (Diagnostic Equipment) | Formerly VC-backed | Alameda, CA |
Locanabio Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Locanabio Patents
Locanabio Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20230279397-A1 | Compositions and methods comprising engineered short nuclear rna (snrna) | Pending | 04-Mar-2022 | ||
| US-20240018521-A1 | Compositions and methods comprising engineered short nuclear rna (snrna) | Active | 04-Mar-2022 | ||
| US-12037588-B2 | Compositions and methods comprising engineered short nuclear rna (snrna) | Active | 04-Mar-2022 | ||
| AU-2023228712-A1 | Compositions and methods comprising engineered small nuclear rna (snrna) | Pending | 04-Mar-2022 | ||
| CA-3216419-A1 | Tissue-targeted modified aav capsids and methods of use thereof | Pending | 23-Apr-2021 | A61K48/0058 |
Locanabio Executive Team (12)
| Name | Title | Board Seat |
|---|---|---|
| Kat Lange | Chief Financial Officer | |
| Edward Conner MD | Chairman of Scientific Advisory Board |
Locanabio Board Members (8)
| Name | Representing | Role | Since |
|---|---|---|---|
| Edward Conner MD | Self | Chairman of Scientific Advisory Board | |
| Jean George | Lightstone Ventures | Board Member | |
| Jeffrey Ostrove Ph.D | Self | Board Member | |
| Rajul Jain MD | Vida Ventures (Boston) | Board Member | |
| Thomas Daniel MD | ARCH Venture Partners | Chairman |
Locanabio Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Locanabio Investors (14)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| CureDuchenne Ventures | Corporate Venture Capital | Minority | ||
| Acuta Capital Partners | Hedge Fund | Minority | ||
| Leerink Partners | Investment Bank | Minority | ||
| RA Capital Management | Venture Capital | Minority | ||
| The Invus Group | PE/Buyout | Minority |
Locanabio FAQs
-
When was Locanabio founded?
Locanabio was founded in 2016.
-
Who is the founder of Locanabio?
Richard Schneeberger Ph.D, David Nelles Ph.D, and Eugene Yeo Ph.D are the founders of Locanabio.
-
Where is Locanabio headquartered?
Locanabio is headquartered in San Diego, CA.
-
What is the size of Locanabio?
Locanabio has 64 total employees.
-
What industry is Locanabio in?
Locanabio’s primary industry is Other Healthcare Technology Systems.
-
Is Locanabio a private or public company?
Locanabio is a Private company.
-
What is Locanabio’s current revenue?
The current revenue for Locanabio is .
-
How much funding has Locanabio raised over time?
Locanabio has raised $159M.
-
Who are Locanabio’s investors?
CureDuchenne Ventures, Acuta Capital Partners, Leerink Partners, RA Capital Management, and The Invus Group are 5 of 14 investors who have invested in Locanabio.
-
Who are Locanabio’s competitors?
PepGen, NeuBase Therapeutics, WaVe Life Sciences, Voyager Therapeutics, and Fluxion (Diagnostic Equipment) are some of the 23 competitors of Locanabio.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
